SG10202010429YA - Targeting of cytokine antagonists - Google Patents
Targeting of cytokine antagonistsInfo
- Publication number
- SG10202010429YA SG10202010429YA SG10202010429YA SG10202010429YA SG10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA SG 10202010429Y A SG10202010429Y A SG 10202010429YA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- fusion protein
- ifn
- antagonist
- cytokine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306045 | 2013-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202010429YA true SG10202010429YA (en) | 2020-11-27 |
Family
ID=48874233
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010429YA SG10202010429YA (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
| SG11201600165WA SG11201600165WA (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600165WA SG11201600165WA (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9732135B2 (enExample) |
| EP (1) | EP3022230B1 (enExample) |
| JP (1) | JP6475712B2 (enExample) |
| KR (1) | KR102305608B1 (enExample) |
| CN (3) | CN122465024A (enExample) |
| AU (1) | AU2014292355B2 (enExample) |
| CA (1) | CA2918119C (enExample) |
| IL (1) | IL243459B (enExample) |
| MX (1) | MX375426B (enExample) |
| SG (2) | SG10202010429YA (enExample) |
| WO (1) | WO2015007520A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| US9732135B2 (en) * | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CA3016589A1 (en) * | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding agents and uses thereof |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| EP3664829A4 (en) | 2017-08-09 | 2021-05-05 | Orionis Biosciences, Inc. | LIAISON OFFICERS AT PD-1 AND PD-L1 |
| EP3665201A4 (en) * | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| CN117924493A (zh) | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| US12655186B2 (en) | 2018-01-26 | 2026-06-16 | Orionis Biosciences, Inc. | Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2 |
| CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| CN113840833B (zh) | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| WO2020198665A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| US12544426B2 (en) | 2019-06-19 | 2026-02-10 | Orionis Biosciences, Inc. | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes |
| WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| KR20250048583A (ko) | 2022-08-18 | 2025-04-09 | 리제너론 파아마슈티컬스, 인크. | 인터페론 전구단백질 및 이의 용도 |
| KR20260026098A (ko) | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489116B1 (en) | 1989-08-22 | 1994-04-06 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| JP2001502521A (ja) * | 1996-04-26 | 2001-02-27 | ベス イスラエル デアコネス メディカル センター | インターロイキン―１５の拮抗剤 |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| JP5208733B2 (ja) * | 2005-06-29 | 2013-06-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 組換えインターフェロンα２（ＩＦＮα２）変異体 |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| EP2388266B1 (en) * | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| WO2010030671A1 (en) * | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| RU2583876C2 (ru) | 2009-08-17 | 2016-05-10 | Роше Гликарт Аг | Иммуноконъюгаты направленного действия |
| CN102497885A (zh) | 2009-09-10 | 2012-06-13 | 赛托斯生物技术公司 | 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途 |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| CN104203982B (zh) * | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| US9732135B2 (en) * | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
-
2014
- 2014-07-01 US US14/905,348 patent/US9732135B2/en active Active
- 2014-07-01 AU AU2014292355A patent/AU2014292355B2/en active Active
- 2014-07-01 EP EP14734166.3A patent/EP3022230B1/en active Active
- 2014-07-01 SG SG10202010429YA patent/SG10202010429YA/en unknown
- 2014-07-01 WO PCT/EP2014/063976 patent/WO2015007520A1/en not_active Ceased
- 2014-07-01 CA CA2918119A patent/CA2918119C/en active Active
- 2014-07-01 KR KR1020167002677A patent/KR102305608B1/ko active Active
- 2014-07-01 CN CN202610523704.XA patent/CN122465024A/zh active Pending
- 2014-07-01 CN CN201480040656.4A patent/CN105658669A/zh active Pending
- 2014-07-01 MX MX2016000721A patent/MX375426B/es active IP Right Grant
- 2014-07-01 CN CN202610523705.4A patent/CN122562965A/zh active Pending
- 2014-07-01 SG SG11201600165WA patent/SG11201600165WA/en unknown
- 2014-07-01 JP JP2016526507A patent/JP6475712B2/ja active Active
-
2016
- 2016-01-04 IL IL24345916A patent/IL243459B/en active IP Right Grant
-
2017
- 2017-07-06 US US15/642,989 patent/US10072059B2/en active Active
-
2018
- 2018-06-14 US US16/008,695 patent/US20180334489A1/en not_active Abandoned
- 2018-06-14 US US16/008,686 patent/US10947288B2/en active Active
-
2021
- 2021-02-09 US US17/171,433 patent/US20210238247A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016000721A (es) | 2016-09-07 |
| US10947288B2 (en) | 2021-03-16 |
| US20180334489A1 (en) | 2018-11-22 |
| CN105658669A (zh) | 2016-06-08 |
| IL243459A0 (en) | 2016-03-31 |
| AU2014292355A1 (en) | 2016-02-04 |
| EP3022230A1 (en) | 2016-05-25 |
| US20180334488A1 (en) | 2018-11-22 |
| JP6475712B2 (ja) | 2019-02-27 |
| US9732135B2 (en) | 2017-08-15 |
| MX375426B (es) | 2025-03-06 |
| CN122562965A (zh) | 2026-08-14 |
| CA2918119C (en) | 2022-11-29 |
| SG11201600165WA (en) | 2016-02-26 |
| AU2014292355B2 (en) | 2019-08-01 |
| US20160159875A1 (en) | 2016-06-09 |
| KR102305608B1 (ko) | 2021-09-28 |
| US20210238247A1 (en) | 2021-08-05 |
| CA2918119A1 (en) | 2015-01-22 |
| EP3022230B1 (en) | 2019-11-06 |
| CN122465024A (zh) | 2026-07-28 |
| JP2016529232A (ja) | 2016-09-23 |
| IL243459B (en) | 2019-10-31 |
| US20180057555A1 (en) | 2018-03-01 |
| WO2015007520A1 (en) | 2015-01-22 |
| US10072059B2 (en) | 2018-09-11 |
| KR20160108292A (ko) | 2016-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243459A0 (en) | Targeting of cytokine antagonists | |
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL243479A0 (en) | New quinazolinones as bromodomain inhibitors | |
| SG11201601493UA (en) | Atomizer | |
| IL241101B (en) | Medicinal uses of empagliflozin | |
| SG11201510297QA (en) | Targeted integration | |
| IL241102A0 (en) | Medicinal uses of empagliflozin | |
| SG11201510215VA (en) | Injector | |
| GB201319791D0 (en) | Formulations | |
| GB201314381D0 (en) | Injector | |
| SI2981271T1 (sl) | Terapevtske uporabe empagliflozina | |
| AU355193S (en) | Injector | |
| ZA201604502B (en) | Use of benzimidazole-proline derivatives | |
| HUP1300139A2 (en) | Phenoxypiperidine h3 antagonists | |
| ZA201602831B (en) | Use of lactones | |
| PL3063152T3 (pl) | Dogodne wytwarzanie n-podstawionych morfinan-6-oli z morfinan-6-onów | |
| IL244537A0 (en) | New administration preparations and methods of their use | |
| GB201319437D0 (en) | Delivery of drugs | |
| PL3049378T3 (pl) | Wytwarzanie radiojodowanego 3-fluoropropylo-nor-beta-CIT | |
| TWM475821U (en) | Structure of mosquito-catch | |
| GB201318284D0 (en) | Construction of surfaces | |
| PL3071575T3 (pl) | Wytwarzanie normorfinanów | |
| TWM475524U (en) | Structure of rivet-pulling | |
| GB201304608D0 (en) | BenTime of Yisrael operable arrangement | |
| TWM475672U (en) | Improved structure of signage |